Diabetes and prediabetes prevail among obstructive sleep apnea (OSA) patients. OSA and short sleep both detrimentally affect glycemic control regardless of obesity. With 1 in 10 adults having diabetes, 1 in 10 with prediabetes, and an estimated 600,000 affected by OSA in Sweden, attaining glycemic control is crucial. Though continuous positive airway pressure (CPAP) is the most effective treatment for OSA, its application lacks personalization, ignoring factors like comorbidities and sleep duration. Key unanswered questions regarding CPAP's impact on glycemic control include: 1) Does high CPAP adherence optimize glycemic control? 2) Should short sleep be addressed alongside OSA treatment for glycemic control? 3) Does long-term diabetes hinder CPAP's glycemic control efficacy? The purpose of this project is to enable precision health in CPAP treatment and producing a personalized treatment model for achieving glycemic control in patients with OSA, treated with CPAP. Taking advantage of a large unique patient cohort (600 patients followed over 18 months) with extensive and objective measures on CPAP adherence, OSA reduction, sleep duration, as well as information on comorbidities, anthropometric, lifestyle data, and a wide range of biomarkers related to glycemic control. This comprehensive approach and in-depth analysis will address these questions and generate a personalized treatment strategy for glycemic control in CPAP-treated OSA patients.
Study Type
OBSERVATIONAL
Enrollment
600
Uppsala University
Uppsala, Uppsala County, Sweden
RECRUITINGHomeostatic model assessment for insulin resistance (HOMA-IR)
Clinical marker: HOMA-IR calculated from blood glucose and serum insuling
Time frame: From enrollment to the end of treatment at 12 months
Glycated hemoglobin (HbA1c)
Clinical maker: glycated hemoglobin (HbA1c) in % and mmol/mol
Time frame: From enrollment to the end of treatment at 12 months
Blood glucose
Clinical marker: blood glucose in mmol/L
Time frame: From enrollment to the end of treatment at 12 months
Serum insulin
Clinical marker: serum insulin in mU/L
Time frame: From enrollment to the end of treatment at 12 months
Plasma triglycerides
Clinical marker: Triglycerides in mg/dL
Time frame: From enrollment to the end of treatment at 12 months
Plasma cholesterol
Clinical marker: plasma cholesterol in mg/dL
Time frame: From enrollment to the end of treatment at 12 months
HDL-cholesterol
Clinial marker: high-density lipoprotein (HDL) cholesterol in mg/dL
Time frame: From enrollment to the end of treatment at 12 months
LDL-cholesterol
Clinical marker: low-density lipoprotein (LDL) cholesterol in mg/dL
Time frame: From enrollment to the end of treatment at 12 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.